MDR1 genotype-dependent regulation of the aldosterone system in humans

Pharmacogenetics and Genomics

Volumn 17, Issue 2, 2007, Pages 137-144

  Zolk, Oliver ^a   Jacobi, Johannes ^a   Pahl, Andreas ^a   Fromm, Martin F ^a   Schmieder, Roland E ^a  

^a UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

Author keywords

ABCB1; Aldosterone; Blood pressure; Polymorphism

Indexed keywords

ALDOSTERONE; ANGIOTENSIN II; MULTIDRUG RESISTANCE PROTEIN 1; SODIUM;

ADULT; ARTICLE; BLOOD PRESSURE; CAUCASIAN; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; GENOTYPE; HEART LEFT VENTRICLE; HEART LEFT VENTRICLE FUNCTION; HORMONAL REGULATION; HUMAN; KIDNEY FUNCTION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEIN POLYMORPHISM; SODIUM URINE LEVEL; SYSTOLIC BLOOD PRESSURE;

ADULT; ALDOSTERONE; ECHOCARDIOGRAPHY; GENOTYPE; HUMANS; KIDNEY FUNCTION TESTS; MALE; P-GLYCOPROTEIN; POLYMORPHISM, SINGLE NUCLEOTIDE; RENIN-ANGIOTENSIN SYSTEM; SODIUM;

EID: 33847037470     PISSN: 17446872     EISSN: 17446880     Source Type: Journal    
DOI: 10.1097/01.fpc.0000239969.46594.d0     Document Type: Article

References (38)

1. Fromm MF. Importance of P-glycoprotein at blood-tissue barriers. Trends Pharmacol Sci 2004; 25:423-429.
2. Cordon-Cardo C, O'Brien JP, Boccia J, Casals D, Bertino JR, Melamed MR. Expression of the multidrug resistance gene product (P-Glycoprotein) in human normal and tumor tissues. J Histochem Cytochem 1990; 38:1277-1287.
3. Sugawara I, Kataoka I, Morishita Y, Hamada H, Tsuruo T, Itoyama S, et al. Tissue distribution of P-glycoprotein encoded by a multidrug-resistant gene as revealed by a monoclonal antibody, MRK 16. Cancer Res 1988; 48:1926-1929.
4. Thiebaut F, Tsuruo T, Hamada H, Gottesman MM, Pastan I, Willingham MC. Cellular localization of the multidrug-resistance gene product P-glycoprotein in normal human tissues. Proc Natl Acad Sci U S A 1987; 84:7735-7738.
5. Ueda K, Okamura N, Hirai M, Tanigawara Y, Saeki T, Kioka N, et al. Human P-glycoprotein transports cortisol, aldosterone, and dexamethasone, but not progesterone. J Biol Chem 1992; 267:24248-24252.
6. Bello-Reuss E, Ernest S, Holland OB, Hellmich MR. Role of multidrug resistance P-glycoprotein in the secretion of aldosterone by human adrenal NCI-H295 cells. Am J Physiol Cell Physiol 2000; 278:C1256-C1265.
7. Sugawara I, Hamada H, Nakahama M, Okamoto S, Tsuruo T, Mori S. Further characterization of the human adrenal-derived P-glycoprotein recognized by monoclonal antibody MRK 16 reacting with only human P-glycoprotein. Jpn J Cancer Res 1989; 80:1199-1205.
8. Connell JM, Davies E. The new biology of aldosterone. J Endocrinol 2005; 186:1-20.
9. Ernest S, Rajaraman S, Megyesi J, Bello-Reuss EN. Expression of MDR1 (multidrug resistance) gene and its protein in normal human kidney. Nephron 1997; 77:284-289.
10. Pitt B, Zannad F, Remme WJ, Cody R, Castaigne A, Perez A, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized aldactone evaluation study investigators. N Engl J Med 1999; 341:709-717.
11. Meissner K, Sperker B, Karsten C, Zu Schwabedissen HM, Seeland U, Bohm M, et al. Expression and localization of P-glycoprotein in human heart: effects of cardiomyopathy. J Histochem Cytochem 2002; 50:1351-1356.
12. Gerloff T. Impact of genetic polymorphisms in transmembrane carrier-systems on drug and xenobiotic distribution. Naunyn Schmiedebergs Arch Pharmacol 2004; 369:69-77.
13. Hoffmeyer S, Burk O, von RO, Arnold HP, Brockmoller J, Johne A, et al. Functional polymorphisms of the human multidrug-resistance gene: multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo. Proc Natl Acad Sci U S A 2000; 97:3473-3478.
14. Pauli-Magnus C, Kroetz DL. Functional implications of genetic polymorphisms in the multidrug resistance gene MDR1 (ABCB1). Pharm Res 2004; 21:904-913.
15. Schwab M, Eichelbaum M, Fromm MF. Genetic polymorphisms of the human MDR1 drug transporter. Annu Rev Pharmacol Toxicol 2003; 43:285-307.
16. Fromm MF. The influence of MDR1 polymorphisms on P-glycoprotein expression and function in humans. Adv Drug Deliv Rev 2002; 54:1295-1310.
17. Siegmund W, Ludwig K, Giessmann T, Dazert P, Schroeder E, Sperker B, et al. The effects of the human MDR1 genotype on the expression of duodenal P-glycoprotein and disposition of the probe drug talinolol. Clin Pharmacol Ther 2002; 72:572-583.
18. Lepper ER, Nooter K, Verweij J, Acharya MR, Figg WD, Sparreboom A. Mechanisms of resistance to anticancer drugs: the role of the polymorphic ABC transporters ABCB1 and ABCG2. Pharmacogenomics 2005; 6:115-138.
19. Siegsmund M, Brinkmann U, Schaffeler E, Weirich G, Schwab M, Eichelbaum M, et al. Association of the P-glycoprotein transporter MDR1(C3435T) polymorphism with the susceptibility to renal epithelial tumors. J Am Soc Nephrol 2002; 13:1847-1854.
20. Delles C, Erdmann J, Jacobi J, Hilgers KF, Fleck E, Regitz-Zagrosek V, et al. Aldosterone synthase (CYP11B2) -344 C/T polymorphism is associated with left ventricular structure in human arterial hypertension. J Am Coll Cardiol 2001; 37:878-884.
21. Schlaich MP, Schobel HP, Hilgers K, Schmieder RE. Impact of aldosterone on left ventricular structure and function in young normotensive and mildly hypertensive subjects. Am J Cardiol 2000; 85:1199-1206.
22. Hilgers KF, Langenfeld MR, Schlaich M, Veelken R, Schmieder RE. 1166 A/C polymorphism of the angiotensin II type 1 receptor gene and the response to short-term infusion of angiotensin II. Circulation 1999; 100:1394-1399.
23. Fromm MF, Schmidt BM, Pahl A, Jacobi J, Schmieder RE. CYP3A5 genotype is associated with elevated blood pressure. Pharmacogenet Genomics 2005; 15:737-741.
24. Miller JA, Anacta LA, Cattran DC. Impact of gender on the renal response to angiotensin II. Kidney Int 1999; 55:278-285.
25. European Society of Hypertension-European Society of Cardiology Guidelines Committee. 2003 European Society of Hypertension-European Society of Cardiology guidelines for the management of arterial hypertension. J Hypertens 2003; 21:1011-1053.
26. Chambers S, Nicholls MG, Espiner EA, Ikram H, Livesey JH. Hormone and haemodynamic effects of angiotensin II infusion during captopril treatment for heart failure. Horm Metab Res 1985; 17:159-162.
27. van der Linde NA, Sijbrands EJ, Boomsma F, van den Meiracker AH. Effect of low-density lipoprotein cholesterol on angiotensin II sensitivity: a randomized trial with fluvastatin. Hypertension 2006; 47:1125-1130.
28. Saitoh M, Yanagawa T, Kondoh T, Miyakoda H, Kotake H, Mashiba H. Neurohumoral factor responses to mental (arithmetic) stress and dynamic exercise in normal subjects. Intern Med 1995; 34:618-622.
29. Schmieder RE, Gatzka C, Schobel H, Schachinger H, Weihprecht H. Renal hemodynamic response to stress is influenced by ACE-inhibitors. Clin Nephrol 1994; 42:381-388.
30. Cole BR, Giangiacomo J, Ingelfinger JR, Robson AM. Measurement of renal function without urine collection. A critical evaluation of the constant-infusion technique for determination of inulin and para-aminohippurate. N Engl J Med 1972; 287:1109-1114.
31. Lijnen P, M'Buyamba-Kabangu JR, Fagard RH, Groeseneken DR, Staessen JA, Amery AK. Intracellular concentration and transmembrane fluxes of sodium and potassium in erythrocytes of white normal male subjects with and without a family history of hypertension. J Hypertens 1984; 2:25-30.
32. Schmieder RE, Langenfeld MR, Friedrich A, Schobel HP, Gatzka CD, Weihprecht H. Angiotensin II related to sodium excretion modulates left ventricular structure in human essential hypertension. Circulation 1996; 94:1304-1309.
33. Siersbaek-Nielsen K, Hansen JM, Kampmann J, Kristensen M. Rapid evaluation of creatinine clearance. Lancet 1971; 1:1133-1134.
34. Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron 1976; 16:31-41.
35. Wang D, Johnson AD, Papp AC, Kroetz DL, Sadee W. Multidrug resistance polypeptide 1 (MDR1, ABCB1) variant 3435C>T affects mRNA stability. Pharmacogenet Genomics 2005; 15:693-704.
36. Hitzl M, Drescher S, van der KH, Schaffeler E, Fischer J, Schwab M, et al. The C3435T mutation in the human MDR1 gene is associated with altered efflux of the P-glycoprotein substrate rhodamine 123 from CD56+ natural killer cells. Pharmacogenetics 2001; 11:293-298.
37. Parker RB, Yates CR, Laizure SC, Weber KT. P-glycoprotein modulates aldosterone plasma disposition and tissue uptake. J Cardiovasc Pharmacol 2006; 47:55-59.
38. Gfeller J, Siegenthaler W. Renal clearance of aldosterone and its metabolite in man. Acta Endocrinol 1965; 49:510-524.